In a Nutshell
Tesamorelin is FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss or body-composition treatment.
Tesamorelin is a GHRH analog — the same class as sermorelin — that stimulates your pituitary to release your own growth hormone.
It is FDA-approved, marketed as Egrifta, and that approval is real and current. But it is narrow: the indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy 1 — a specific metabolic complication of HIV and its treatment.
That distinction gets flattened constantly. "Tesamorelin is FDA-approved for visceral fat" is the claim you will see. The accurate version is "tesamorelin is FDA-approved for visceral fat in adults with HIV-associated lipodystrophy," and the difference is the entire population studied.
Use for general visceral fat reduction, body composition or anti-aging in people without that condition is off-label, and is not supported by the trials that produced the approval.
How It Compares to Sermorelin
Both are GHRH analogs, both stimulate endogenous growth hormone release, and both leave the amount of growth hormone released under the pituitary's own regulation, which an injected dose of growth hormone is not.
| Sermorelin | Tesamorelin | |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Mechanism | Stimulates pituitary GH release | Stimulates pituitary GH release |
| FDA status | Previously approved (GEREF); now compounded | Currently approved as Egrifta |
| Approved indication | (Historically) pediatric GHD; diagnostic | HIV-associated lipodystrophy — visceral fat |
| Controlled trials outside the approved indication | Two small adult trials (cognition in older adults; HIV lipodystrophy); none for general wellness | Yes — abdominally obese adults with reduced GH secretion (12-month RCT, n=60: visceral fat reduced) 8, plus smaller trials for liver fat and cognition; none for general wellness |
| On FDA Category 2 or withdrawn lists | No | No |
The mechanistic similarity is why the two get compared. The practical differences are the indication, the cost, and the fact that tesamorelin's approval — while genuine — describes a population most people asking about it do not belong to.
What the Evidence Shows
Evidence tier: A for the approved indication. C for general wellness use.
The approval trials demonstrated meaningful reductions in visceral adipose tissue in adults with HIV-associated lipodystrophy. That is solid evidence for that population.
Two things it does not establish:
That the effect transfers to the general population. HIV-associated lipodystrophy involves a distinctive pattern of fat redistribution driven by the infection and its treatment. Visceral fat accumulation in the general population — driven by insulin resistance, hormonal change, diet and activity — is a different problem, even though the fat sits in the same place. The one controlled trial outside HIV, described below, was in adults selected for reduced growth hormone secretion — it narrows that gap without closing it.
That it is the right tool for ordinary visceral fat. For visceral fat in the general population, the interventions with strong evidence are the ones that produce overall fat loss — including the approved GLP-1 medications, which reduce visceral fat as part of overall weight reduction. See GLP-1 medications for weight loss.
Tesamorelin has been tested outside HIV, in one trial relevant to this question. A 12-month randomized, double-blind, placebo-controlled study of 60 abdominally obese adults with reduced growth hormone secretion found that tesamorelin 2 mg daily reduced visceral fat (treatment effect −35 cm², P = 0.003) with no change in subcutaneous fat, and improved triglycerides, C-reactive protein and carotid intima-media thickness, without worsening glucose; IGF-1 rose 8. That is a real controlled result in a non-HIV population — but it is a single trial in a selected group (reduced GH secretion, confirmed by testing), it measured fat compartments and risk markers rather than weight or outcomes, and it is not an approved indication. Smaller controlled studies have also tested tesamorelin for liver fat and for cognition in older adults. None of this is evidence for general wellness use.
There is also discontinuation: reductions in visceral fat were not maintained after treatment stopped. That raises an important duration question — but it does not establish that indefinite treatment is appropriate, and the label states that long-term cardiovascular safety has not been established.
Safety Considerations
Because Egrifta has a label, its profile is documented rather than inferred. The label contraindicates use in pregnancy, active malignancy, hypersensitivity, and conditions that disrupt the hypothalamic-pituitary axis (including relevant pituitary disease, surgery, irradiation or trauma), and warns on persistent IGF-1 elevation, glucose intolerance and diabetes, diabetic retinopathy progression, fluid retention, hypersensitivity, acute critical illness, injection-site reactions, and interactions involving CYP450-metabolized drugs and glucocorticoids.
Long-term cardiovascular safety has not been established. A substantial share of treated patients developed markedly elevated IGF-1 — directly relevant to the point made elsewhere on this hub that retained feedback does not guarantee levels stay in range.
These findings apply to the approved product and indication and should not be transferred casually to every GHRH analog. The broader themes:
- Glucose and insulin sensitivity — growth hormone reduces insulin sensitivity, so glucose monitoring matters, particularly with diabetes or prediabetes
- Fluid retention — swelling, joint pain, carpal-tunnel-type symptoms
- Injection-site reactions — common
- Malignancy considerations — growth hormone signaling and cell proliferation are linked; active malignancy is a relevant contraindication
- Not appropriate in pregnancy
Consult the prescribing information for the full profile and a clinician for whether it applies to you.
Red Flags — Contact Your Clinician
- Persistent headaches, visual changes or persistent nausea
- New or worsening joint pain, or swelling of hands, feet or ankles
- Numbness or tingling in the hands
- Symptoms of high blood sugar — increased thirst, frequent urination, blurred vision
- Fever, spreading redness, swelling or pus at an injection site
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
On Dosing
This page does not provide dosing protocols. Dosing for the approved indication is specified in the prescribing information and set by the prescriber. There is no established dose for off-label wellness use.
What You Can Do About Visceral Fat
Visceral fat — the metabolically active fat around the organs — is worth taking seriously; it is more strongly associated with cardiometabolic risk than subcutaneous fat. It is also responsive to interventions with real evidence.
- Overall fat loss reduces it, and it often responds earlier than total weight suggests
- GLP-1 medications reduce visceral fat as part of overall weight reduction, with substantial trial evidence
- Resistance training and protein protect lean mass during that process, which matters for keeping results
- Hormonal change drives it in midlife — the redistribution toward abdominal fat in perimenopause and menopause is hormonally mediated and responds to addressing that directly. See visceral fat in menopause
- Sleep and insulin resistance are both contributors and both measurable
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians, with the outcomes of its weight-loss program published in the peer-reviewed literature 7. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning, repeated at visits. InBody scans are done in clinic; online members can book one at any of the 14 locations.
For visceral fat specifically, serial scanning under consistent conditions adds information beyond scale weight — though it estimates body compartments by bioelectrical impedance rather than directly imaging muscle or visceral fat, and is interpreted alongside labs and clinical context. And the metabolic and hormonal drivers behind abdominal fat accumulation are exactly what the lab panel is designed to surface.
Can you get tesamorelin on prescription?
The approved product, Egrifta, is indicated for HIV-associated lipodystrophy and prescribed in that context.
Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.
Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Sermorelin — the other GHRH analog, and the one most often compared with it
- GLP-1 Medications for Weight Loss — the evidence-backed route to visceral fat reduction
- Visceral Fat in Menopause
- Peptides for Weight Loss: What Actually Works
- Are Peptides Legal in the US?
Frequently Asked Questions
Is tesamorelin FDA approved?
Yes — as Egrifta, for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That is a genuine current approval, but it is specific to that condition. Use for general visceral fat or body composition is off-label and not supported by the approval trials.
Does tesamorelin reduce belly fat?
In adults with HIV-associated lipodystrophy, the approval trials showed meaningful reductions in visceral adipose tissue. Whether that transfers to visceral fat in the general population — which has different drivers — has not been established, and visceral fat reaccumulated when treatment stopped in the approval program.
Tesamorelin vs sermorelin — what's the difference?
Both are GHRH analogs working through the same mechanism. Tesamorelin has a current FDA approval for a narrow indication; sermorelin was previously approved and is now supplied compounded. Neither has controlled-trial evidence for general wellness use. Tesamorelin has been tested outside its approved indication — most notably a 12-month randomized trial in abdominally obese adults with reduced GH secretion, which reduced visceral fat 8 — and in smaller trials for liver fat and cognition; sermorelin's two adult trials were narrow.
Is tesamorelin a weight loss drug?
No. Its approved indication concerns visceral fat redistribution in a specific condition, not weight loss. For weight loss, the approved GLP-1 medications have far stronger evidence.
Can anyone get tesamorelin?
The approved product is indicated for adults with HIV-associated lipodystrophy. An approved product may be prescribed for an unapproved use in appropriate clinical circumstances, but FDA has not determined that use to be safe or effective, and the supporting evidence has to come from somewhere other than the approval. For general wellness use it is thin.
References
- Theratechnologies Inc., "EGRIFTA WR (tesamorelin for injection), for subcutaneous use — Prescribing Information," Initial U.S. Approval 2010, revised Mar. 2025. DailyMed, U.S. National Library of Medicine, [Online]. Available: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 [Accessed: Oct. 5, 2026]. ↩
- J. Falutz, S. Allas, K. Blot, D. Potvin, et al., "Metabolic effects of a growth hormone-releasing factor in patients with HIV," New England Journal of Medicine, vol. 357, no. 23, pp. 2359-2370, Dec. 2007, [Online]. Available: https://doi.org/10.1056/NEJMoa072375. PMID: 18057338. [Accessed: Jul. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- I. J. Neeland, R. Ross, J.-P. Després, Y. Matsuzawa, S. Yamashita, I. Shai, J. Seidell, P. Magni, R. D. Santos, B. Arsenault, A. Cuevas, F. B. Hu, B. Griffin, A. Zambon, P. Barter, J.-C. Fruchart, R. H. Eckel; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity, "Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement," The Lancet Diabetes & Endocrinology, vol. 7, no. 9, pp. 715-725, Sep. 2019, [Online]. Available: https://doi.org/10.1016/S2213-8587(19)30084-1. PMID: 31301983. [Accessed: Oct. 5, 2026]. ↩
- C. Liao, X. Liang, X. Zhang, Y. Li, "The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis," PLoS ONE, vol. 18, no. 8, art. no. e0289616, Aug. 2023, [Online]. Available: https://doi.org/10.1371/journal.pone.0289616. PMID: 37616255. PMCID: PMC10449217. [Accessed: Oct. 5, 2026]. ↩
- J. Falutz, S. Allas, J. C. Mamputu, D. Potvin, et al., "Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation," AIDS, vol. 22, no. 14, pp. 1719-1728, Sep. 2008, [Online]. Available: https://doi.org/10.1097/QAD.0b013e32830a5058. PMID: 18690162. [Accessed: Jul. 26, 2026]. ↩
- S. Bourke, J. M. Morton, P. Williams, "Effect of JumpstartMD, a Commercial Low-Calorie Low-Carbohydrate Physician-Supervised Weight Loss Program, on 22,407 Adults," Journal of Obesity, vol. 2020, art. no. 8026016, Apr. 2020, [Online]. Available: https://doi.org/10.1155/2020/8026016. PMID: 32318289. PMCID: PMC7157789. [Accessed: Jul. 26, 2026]. ↩
- H. Makimura, M. N. Feldpausch, A. M. Rope, L. C. Hemphill, M. Torriani, H. Lee, S. K. Grinspoon, "Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial," Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 12, pp. 4769-4779, Dec. 2012, [Online]. Available: https://doi.org/10.1210/jc.2012-2794. PMID: 23015655. PMCID: PMC3513535. [Accessed: Oct. 5, 2026]. ↩